Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$22.28 - $38.71 $9.02 Million - $15.7 Million
-404,871 Reduced 94.13%
25,256 $775,000
Q3 2022

Nov 10, 2022

BUY
$34.2 - $51.69 $3.13 Million - $4.73 Million
91,529 Added 27.03%
430,127 $14.7 Million
Q2 2022

Aug 15, 2022

BUY
$23.14 - $49.68 $1.1 Million - $2.36 Million
47,572 Added 16.35%
338,598 $11.7 Million
Q1 2022

May 16, 2022

SELL
$27.77 - $64.4 $3.53 Million - $8.18 Million
-126,989 Reduced 30.38%
291,026 $12.8 Million
Q4 2021

Feb 14, 2022

BUY
$54.9 - $105.21 $11.5 Million - $22.1 Million
209,964 Added 100.92%
418,015 $26.3 Million
Q3 2021

Nov 15, 2021

SELL
$105.0 - $178.37 $5.67 Million - $9.63 Million
-54,002 Reduced 20.61%
208,051 $21.9 Million
Q2 2021

Aug 16, 2021

SELL
$125.11 - $180.0 $15.2 Million - $21.8 Million
-121,278 Reduced 31.64%
262,053 $46.4 Million
Q1 2021

May 14, 2021

SELL
$126.27 - $191.71 $9.17 Million - $13.9 Million
-72,659 Reduced 15.93%
383,331 $51.1 Million
Q4 2020

Feb 16, 2021

SELL
$81.94 - $135.34 $10.1 Million - $16.6 Million
-122,702 Reduced 21.2%
455,990 $61.7 Million
Q3 2020

Nov 13, 2020

SELL
$73.3 - $89.48 $2.42 Million - $2.95 Million
-33,012 Reduced 5.4%
578,692 $48.1 Million
Q2 2020

Aug 13, 2020

SELL
$48.82 - $82.53 $8.98 Million - $15.2 Million
-183,936 Reduced 23.12%
611,704 $50.2 Million
Q1 2020

May 15, 2020

BUY
$39.1 - $62.9 $9.98 Million - $16.1 Million
255,281 Added 47.24%
795,640 $41 Million
Q4 2019

Feb 14, 2020

SELL
$29.79 - $43.06 $4.81 Million - $6.95 Million
-161,444 Reduced 23.0%
540,359 $22.5 Million
Q3 2019

Nov 14, 2019

SELL
$30.47 - $37.65 $9.52 Million - $11.8 Million
-312,345 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$25.73 - $35.79 $8.04 Million - $11.2 Million
312,345 New
312,345 $10.9 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $3.31B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Indus Capital Partners, LLC Portfolio

Follow Indus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Indus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Indus Capital Partners, LLC with notifications on news.